140 related articles for article (PubMed ID: 19797418)
21. Large-scale immunomagnetic selection of CD14+ monocytes to generate dendritic cells for cancer immunotherapy: a phase I study.
Babatz J; Röllig C; Oelschlägel U; Zhao S; Ehninger G; Schmitz M; Bornhäuser M
J Hematother Stem Cell Res; 2003 Oct; 12(5):515-23. PubMed ID: 14594508
[TBL] [Abstract][Full Text] [Related]
22. Phase I clinical trial using peptide vaccine for human vascular endothelial growth factor receptor 2 in combination with gemcitabine for patients with advanced pancreatic cancer.
Miyazawa M; Ohsawa R; Tsunoda T; Hirono S; Kawai M; Tani M; Nakamura Y; Yamaue H
Cancer Sci; 2010 Feb; 101(2):433-9. PubMed ID: 19930156
[TBL] [Abstract][Full Text] [Related]
23. Dendritic Cell-based Immunotherapy Pulsed With Wilms Tumor 1 Peptide and Mucin 1 as an Adjuvant Therapy for Pancreatic Ductal Adenocarcinoma After Curative Resection: A Phase I/IIa Clinical Trial.
Nagai K; Adachi T; Harada H; Eguchi S; Sugiyama H; Miyazaki Y
Anticancer Res; 2020 Oct; 40(10):5765-5776. PubMed ID: 32988904
[TBL] [Abstract][Full Text] [Related]
24. Phase 1 trial of Wilms tumor 1 (WT1) peptide vaccine and gemcitabine combination therapy in patients with advanced pancreatic or biliary tract cancer.
Kaida M; Morita-Hoshi Y; Soeda A; Wakeda T; Yamaki Y; Kojima Y; Ueno H; Kondo S; Morizane C; Ikeda M; Okusaka T; Takaue Y; Heike Y
J Immunother; 2011 Jan; 34(1):92-9. PubMed ID: 21150717
[TBL] [Abstract][Full Text] [Related]
25. Phase II clinical trial using novel peptide cocktail vaccine as a postoperative adjuvant treatment for surgically resected pancreatic cancer patients.
Miyazawa M; Katsuda M; Maguchi H; Katanuma A; Ishii H; Ozaka M; Yamao K; Imaoka H; Kawai M; Hirono S; Okada KI; Yamaue H
Int J Cancer; 2017 Feb; 140(4):973-982. PubMed ID: 27861852
[TBL] [Abstract][Full Text] [Related]
26. Wilms tumor gene (WT1) peptide-based cancer vaccine combined with gemcitabine for patients with advanced pancreatic cancer.
Nishida S; Koido S; Takeda Y; Homma S; Komita H; Takahara A; Morita S; Ito T; Morimoto S; Hara K; Tsuboi A; Oka Y; Yanagisawa S; Toyama Y; Ikegami M; Kitagawa T; Eguchi H; Wada H; Nagano H; Nakata J; Nakae Y; Hosen N; Oji Y; Tanaka T; Kawase I; Kumanogoh A; Sakamoto J; Doki Y; Mori M; Ohkusa T; Tajiri H; Sugiyama H
J Immunother; 2014; 37(2):105-14. PubMed ID: 24509173
[TBL] [Abstract][Full Text] [Related]
27. Gemcitabine-treated pancreatic cancer cell medium induces the specific CTL antitumor activity by stimulating the maturation of dendritic cells.
Pei Q; Pan J; Zhu H; Ding X; Liu W; Lv Y; Zou X; Luo H
Int Immunopharmacol; 2014 Mar; 19(1):10-6. PubMed ID: 24389382
[TBL] [Abstract][Full Text] [Related]
28. Soluble factors derived from neuroblastoma cell lines suppress dendritic cell differentiation and activation.
Harada K; Ihara F; Takami M; Kamata T; Mise N; Yoshizawa H; Hishiki T; Saito T; Terui K; Nakata M; Komatsu S; Ikeuchi T; Nakayama T; Yoshida H; Motohashi S
Cancer Sci; 2019 Mar; 110(3):888-902. PubMed ID: 30629318
[TBL] [Abstract][Full Text] [Related]
29. Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity.
Suzuki E; Kapoor V; Jassar AS; Kaiser LR; Albelda SM
Clin Cancer Res; 2005 Sep; 11(18):6713-21. PubMed ID: 16166452
[TBL] [Abstract][Full Text] [Related]
30. Uncarinic acid C plus IFN-γ generates monocyte-derived dendritic cells and induces a potent Th1 polarization with capacity to migrate.
Bae WK; Umeyama A; Chung IJ; Lee JJ; Takei M
Cell Immunol; 2010; 266(1):104-10. PubMed ID: 20933226
[TBL] [Abstract][Full Text] [Related]
31. Myeloid blood CD11c(+) dendritic cells and monocyte-derived dendritic cells differ in their ability to stimulate T lymphocytes.
Osugi Y; Vuckovic S; Hart DN
Blood; 2002 Oct; 100(8):2858-66. PubMed ID: 12351396
[TBL] [Abstract][Full Text] [Related]
32. Immunological evaluation of personalized peptide vaccination with gemcitabine for pancreatic cancer.
Yanagimoto H; Mine T; Yamamoto K; Satoi S; Terakawa N; Takahashi K; Nakahara K; Honma S; Tanaka M; Mizoguchi J; Yamada A; Oka M; Kamiyama Y; Itoh K; Takai S
Cancer Sci; 2007 Apr; 98(4):605-11. PubMed ID: 17309598
[TBL] [Abstract][Full Text] [Related]
33. Regulation of development of CD56 bright CD11c + NK-like cells with helper function by IL-18.
Li W; Okuda A; Yamamoto H; Yamanishi K; Terada N; Yamanishi H; Tanaka Y; Okamura H
PLoS One; 2013; 8(12):e82586. PubMed ID: 24376549
[TBL] [Abstract][Full Text] [Related]
34. Perioperative, Spatiotemporally Coordinated Activation of T and NK Cells Prevents Recurrence of Pancreatic Cancer.
Brooks J; Fleischmann-Mundt B; Woller N; Niemann J; Ribback S; Peters K; Demir IE; Armbrecht N; Ceyhan GO; Manns MP; Wirth TC; Kubicka S; Bernhardt G; Smyth MJ; Calvisi DF; Gürlevik E; Kühnel F
Cancer Res; 2018 Jan; 78(2):475-488. PubMed ID: 29180478
[TBL] [Abstract][Full Text] [Related]
35. Dendritic cell immunotherapy combined with gemcitabine chemotherapy enhances survival in a murine model of pancreatic carcinoma.
Ghansah T; Vohra N; Kinney K; Weber A; Kodumudi K; Springett G; Sarnaik AA; Pilon-Thomas S
Cancer Immunol Immunother; 2013 Jun; 62(6):1083-91. PubMed ID: 23604104
[TBL] [Abstract][Full Text] [Related]
36. Phenotype and function of human dendritic cells derived from M-DC8(+) monocytes.
de Baey A; Mende I; Riethmueller G; Baeuerle PA
Eur J Immunol; 2001 Jun; 31(6):1646-55. PubMed ID: 11385608
[TBL] [Abstract][Full Text] [Related]
37. CpG-A oligonucleotides induce a monocyte-derived dendritic cell-like phenotype that preferentially activates CD8 T cells.
Krug A; Rothenfusser S; Selinger S; Bock C; Kerkmann M; Battiany J; Sarris A; Giese T; Speiser D; Endres S; Hartmann G
J Immunol; 2003 Apr; 170(7):3468-77. PubMed ID: 12646607
[TBL] [Abstract][Full Text] [Related]
38. Tumoricidal efficacy coincides with CD11c up-regulation in antigen-specific CD8(+) T cells during vaccine immunotherapy.
Takeda Y; Azuma M; Matsumoto M; Seya T
J Exp Clin Cancer Res; 2016 Sep; 35(1):143. PubMed ID: 27619885
[TBL] [Abstract][Full Text] [Related]
39. Proapoptotic and antiapoptotic proteins of the Bcl-2 family regulate sensitivity of pancreatic cancer cells toward gemcitabine and T-cell-mediated cytotoxicity.
Bauer C; Hees C; Sterzik A; Bauernfeind F; Mak'Anyengo R; Duewell P; Lehr HA; Noessner E; Wank R; Trauzold A; Endres S; Dauer M; Schnurr M
J Immunother; 2015 Apr; 38(3):116-26. PubMed ID: 25751501
[TBL] [Abstract][Full Text] [Related]
40. [A phase I study of combination-therapy with gemcitabine and epitope peptides derived from human vascular endothelial growth factor receptor for unresectable or recurrent pancreas cancer].
Kim DH; Shiozawa S; Usui T; Yoshimatsu K; Otani T; Tsunoda T; Nakamura Y; Ogawa K
Gan To Kagaku Ryoho; 2008 Nov; 35(12):2271-3. PubMed ID: 19106593
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
